3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1/2
2
Phase 1
2
Status
Unknown
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Dermatologic
2
Conditions
Breast Neoplasms
16
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Neoplasm Metastasis
2
Melanoma
2
Leukemia, Myeloid, Acute
2
Head and Neck Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Diseases
2
Uterine Cervical Neoplasms
1
Solid Tumors Refractory to Standard Therapy
1
Solid Tumors
1
Solid Tumor, Adult
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Liposarcoma, Myxoid
1
Liposarcoma
1
Kidney Neoplasms
1
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
1
Hereditary Sensory and Autonomic Neuropathies
1
HER2-positive Breast Cancer
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
ER+ HER2- Advanced Breast Cancer
1
Interventions
pembrolizumab
74
Nivolumab
53
Ipilimumab
42
Cyclophosphamide
32
Interleukin-2
24
aldesleukin
23
Temozolomide
17
fludarabine
16
Biopsy
11
trametinib
10
fludarabine phosphate
10
dabrafenib
10
spartalizumab
8
Paclitaxel
8
Dacarbazine
8
sargramostim
7
cemiplimab
7
binimetinib
7
Cisplatin
7
Bevacizumab
7
poly ICLC
6
lenvatinib
6
epacadostat
6
Radiotherapy
6
Granulocyte-Macrophage Colony-Stimulating Factor
6
montanide ISA 51
5
encorafenib
5
atezolizumab
5
Vemurafenib
5
Specimen Handling
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Melanoma
×
palbociclib
×
Clear all
NCT04720768
2024-01-05
CELEBRATE
Peter MacCallum Cancer Centre, Australia
Phase 1/2
Unknown
78 enrolled
NCT02202200
2016-04-18
OPTIMUM
Assistance Publique - Hôpitaux de Paris
Phase 1/2
Unknown
40 enrolled